As competition intensifies in the obesity treatment market, a next-generation therapy may be in development.
The double-blind, dose-finding ZUPREME-1 trial enrolled 485 adults with overweight or obesity
The Danish biotech company confirmed the global study will begin in the second half of 2026
Landmark agreement opens market access, mobility pathways, and institutional collaboration for Ayurveda, Yoga, and holistic healthcare services
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
The companies aim to expand treatment options for millions living with metabolic disorders
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
